share_log

Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%

Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%

深圳海王星生物工程(SZSE:000078)本週下跌5.4%,使五年跌幅達到46%,進一步疲軟
Simply Wall St ·  03/26 10:47

Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. So we wouldn't blame long term Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) shareholders for doubting their decision to hold, with the stock down 47% over a half decade. And it's not just long term holders hurting, because the stock is down 27% in the last year. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days.

理想情況下,您的整體投資組合應超過市場平均水平。但是在任何投資組合中,個股之間的結果都會好壞參半。因此,我們不會責怪深圳海王星生物工程有限公司(深圳證券交易所:000078)的長期股東對他們的持股決定表示懷疑,該股在五年內下跌了47%。而且,受傷害的不僅僅是長揸者,因爲該股去年下跌了27%。股東們最近的表現更加艱難,股價在過去90天中下跌了24%。

Since Shenzhen Neptunus Bioengineering has shed CN¥385m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於深圳海王生物工程在過去7天內已從其價值下跌了3.85億元人民幣,讓我們看看長期下跌是否是由該企業的經濟推動的。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

儘管一些人繼續教導高效市場假說,但事實證明,市場是反應過度的動態系統,投資者並不總是理性的。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

In the last half decade Shenzhen Neptunus Bioengineering saw its share price fall as its EPS declined below zero. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

在過去的五年中,由於每股收益降至零以下,深圳海王生物工程的股價下跌。由於該公司已跌至虧損狀態,因此很難將每股收益的變化與股價的變化進行比較。但是,我們可以說,在這種情況下,我們預計股價將下跌。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖描述了 EPS 隨着時間的推移是如何變化的(點擊圖片可以看到確切的值)。

earnings-per-share-growth
SZSE:000078 Earnings Per Share Growth March 26th 2024
SZSE: 000078 每股收益增長 2024 年 3 月 26 日

Dive deeper into Shenzhen Neptunus Bioengineering's key metrics by checking this interactive graph of Shenzhen Neptunus Bioengineering's earnings, revenue and cash flow.

查看這張深圳海王生物工程收益、收入和現金流的交互式圖表,深入了解深圳海王生物工程的關鍵指標。

A Different Perspective

不同的視角

While the broader market lost about 13% in the twelve months, Shenzhen Neptunus Bioengineering shareholders did even worse, losing 27%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Shenzhen Neptunus Bioengineering you should know about.

儘管整個市場在十二個月中下跌了約13%,但深圳海王星生物工程股東的表現甚至更糟,下跌了27%。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨8%的總虧損。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,考慮風險。每家公司都有它們,我們已經發現了兩個你應該知道的深圳海王星生物工程的警告信號。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論